Cabaletta Bio, Inc.

A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T cell products to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses. At Cabaletta, we are committed to transforming the treatment of B cell-mediated autoimmune diseases by utilizing our innovative and modular CAAR T platform to develop highly specific products that offer the potential for deep, durable and potentially curative responses for patients with autoimmune diseases. We are a clinical-stage biotechnology company working to develop and launch potentially breakthrough engineered T cell therapies for patients with B cell-mediated autoimmune diseases.